SynthesisDeutsches Arzteblatt international2010
The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication.
Synthesis in Deutsches Arzteblatt international, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.The Cochrane database of systematic reviews · 2015Pooled it
- Newer generation antidepressants for depressive disorders in children and adolescents.The Cochrane database of systematic reviews · 2012Pooled it
- The effect of specialized cancer treatment centers on treatment efficacy in Hodgkin's lymphoma.Deutsches Arzteblatt international · 2012Trial
- Assessing uptake of the macular degeneration core outcome set in clinical trials: a cross-sectional study.BMJ open · 2025Observational
- Article
- From embodiment to evidence: The harmful intersection of poor regulation of medical implants and obstructed narratives in embodied experiences of failed metal-on-metal hips.Health (London, England : 1997) · 2024Article
- A Proposal to Increase Value and Equity in the Development and Distribution of New Pharmaceuticals.International journal of health services : planning, administration, evaluation · 2022Article
- Article
- Analysis of Funding Source and Spin in the Reporting of Studies of Intravitreal Corticosteroid Therapy for Diabetic Macular Edema: A Systematic Review.Clinical ophthalmology (Auckland, N.Z.) · 2020Review
- Relationship Between Declarations of Conflict of Interests and Reporting Positive Outcomes in Iranian Dental Journals.Science and engineering ethics · 2019Review
- Mandatory Research Biopsy Requirements Delay Initiation of Clinical Trials.Frontiers in oncology · 2019Article
- The relationship of study and authorship characteristics on trial sponsorship and self-reported conflicts of interest among neuro-oncology clinical trials.Journal of neuro-oncology · 2018Article
- Article
- The relationship between the physician and pharmaceutical industry: background ethics and regulation proposals.Croatian medical journal · 2016Article
- Does the pharmaceutical industry influence guidelines?: two examples from Germany.Deutsches Arzteblatt international · 2013Article
- The epistemic integrity of scientific research.Science and engineering ethics · 2013Article
- Medical students' attitudes to and contact with the pharmaceutical industry: a survey at eight German university hospitals.Deutsches Arzteblatt international · 2013Article
- Article
- On markets and morals--(re-)establishing independent decision making in healthcare: a reply to Joao Calinas-Correia.Medicine, health care, and philosophy · 2013Article
- Of mugs, meals and more: the intricate relations between physicians and the medical industry.Medicine, health care, and philosophy · 2013Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn recent years, a number of studies have shown that clinical drug trials financed by pharmaceutical companies yield favorable results for company products more often than independent trials do. Moreover, pharmaceutical companies have been found to influence drug trials in various ways. This overview of current, systematic studies on this topic is intended to identify and characterize the particular aspects of the performance of a drug trial that can be affected by financial support from a pharmaceutical company.
methodsPublications retrieved from a systematic Medline search on this topic from 1 November 2002 to 16 December 2009 were independently evaluated and selected by two of the authors. These publications were supplemented by further ones found in their references sections.
results57 publications were included for evaluation in Parts 1 and 2 of this article. A number of studies revealed that many trials financed by pharmaceutical companies-in some cases, as many as half of all such trials-are never published. Moreover, multiple publications of the same findings were found, and some reports were found to include selectively published data. Further studies revealed evidence of other problems including incomplete trial registration, constraints on publishing rights, withheld knowledge of adverse drug reactions, and the use of ghostwriters who were supplied by the pharmaceutical companies.
conclusionFinancial support from a pharmaceutical company influences multiple aspects of the performance of drug trials and often leads to a favorable result for the corporate sponsor of the trial. Public access to trial protocols and results must be ensured. Moreover, more effort should be made to carry out drug trials independently, without the financial support of pharmaceutical companies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.